Cagrilintide · research summary

Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.

Annals of medicine and surgery (2012) · 2026. Summary drawn from the study's full text. Each statement is followed by the exact sentence it comes from. This is a research summary, not medical advice.

Study type

Systematic review and meta-analysis of randomized controlled trials
“This systematic review and meta-analysis evaluated their efficacy and safety in adults with overweight or obesity.”

Subjects

Adults with overweight or obesity, including those with and without type 2 diabetes
“Eligible studies were RCTs that: (1) enrolled adults (≥18 years) with overweight or obesity, with or without type 2 diabetes”

Sample size

5425 participants across four randomized controlled trials
“Four RCTs encompassing 5425 participants were included.”

Duration

Treatment durations ranging from 20 weeks to 68 weeks
“The study designs were consistently randomized, double-blind, and placebo-controlled, with treatment durations ranging from 20 weeks to 68 weeks.”

Reported findings

Cagrilintide monotherapy resulted in significant reductions in body weight and blood pressure, but no meaningful improvement in HbA1c
“Cagrilintide monotherapy produced significant reductions in body weight (MD: −6.08%; MD: −5.89 kg) and blood pressure, without meaningful HbA1c improvement.”
CagriSema significantly reduced body weight, waist circumference, systolic blood pressure, and HbA1c
“CagriSema significantly reduced body weight (MD: −5.98%; MD: −4.68 kg), waist circumference (MD: −10.91 cm), systolic blood pressure, and HbA1c.”
Both treatments showed statistically significant increases in adverse events
“Both treatments showed modest but statistically significant increases in adverse events.”

Limitations stated by the authors

Limited number of included RCTs, substantial heterogeneity across outcomes, and lack of long-term data
“The first limitation is the insufficient number of RCTs included in the study due to the relatively early phase of the development of Cagrilintide and CagriSema, which can affect the estimation and precision of pooled effect sizes and the possibility of conducting reliable subgroup analyses.”

Source: PubMed 42583410 · DOI 10.1097/MS9.0000000000005353 · all study summaries

Reported findings

Cagrilintide monotherapy resulted in significant reductions in body weight and blood pressure, but no meaningful improvement in HbA1c

“Cagrilintide monotherapy produced significant reductions in body weight (MD: −6.08%; MD: −5.89 kg) and blood pressure, without meaningful HbA1c improvement.”

CagriSema significantly reduced body weight, waist circumference, systolic blood pressure, and HbA1c

“CagriSema significantly reduced body weight (MD: −5.98%; MD: −4.68 kg), waist circumference (MD: −10.91 cm), systolic blood pressure, and HbA1c.”

Both treatments showed statistically significant increases in adverse events

“Both treatments showed modest but statistically significant increases in adverse events.”

Limitations stated by the authors

Limited number of included RCTs, substantial heterogeneity across outcomes, and lack of long-term data

“The first limitation is the insufficient number of RCTs included in the study due to the relatively early phase of the development of Cagrilintide and CagriSema, which can affect the estimation and precision of pooled effect sizes and the possibility of conducting reliable subgroup analyses.”